albuterol has been researched along with Dermatitis, Eczematous in 3 studies
Albuterol: A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.
albuterol : A member of the class of phenylethanolamines that is 4-(2-amino-1-hydroxyethyl)-2-(hydroxymethyl)phenol having a tert-butyl group attached to the nirogen atom. It acts as a beta-adrenergic agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD).
Excerpt | Relevance | Reference |
---|---|---|
"We randomly assigned 182 children (6 to 17 years of age), who had uncontrolled asthma while receiving 100 microg of fluticasone twice daily, to receive each of three blinded step-up therapies in random order for 16 weeks: 250 microg of fluticasone twice daily (ICS step-up), 100 microg of fluticasone plus 50 microg of a long-acting beta-agonist twice daily (LABA step-up), or 100 microg of fluticasone twice daily plus 5 or 10 mg of a leukotriene-receptor antagonist daily (LTRA step-up)." | 5.14 | Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. ( Bacharier, LB; Boehmer, SJ; Covar, RA; Guilbert, TW; Jackson, DJ; Larsen, G; Lemanske, RF; Martinez, FD; Mauger, DT; Morgan, WJ; Moss, MH; Sorkness, CA; Spahn, JD; Strunk, RC; Szefler, SJ; Taussig, LM; Zeiger, RS, 2010) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (33.33) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (66.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Malka, J | 1 |
Mauger, DT | 2 |
Covar, R | 1 |
Rabinovitch, N | 1 |
Lemanske, RF | 2 |
Spahn, JD | 2 |
Strunk, RC | 2 |
Zeiger, RS | 2 |
Morgan, WJ | 2 |
Szefler, SJ | 2 |
Sorkness, CA | 1 |
Jackson, DJ | 1 |
Boehmer, SJ | 1 |
Martinez, FD | 1 |
Bacharier, LB | 1 |
Covar, RA | 1 |
Guilbert, TW | 1 |
Larsen, G | 1 |
Moss, MH | 1 |
Taussig, LM | 1 |
Parker, CW | 1 |
Kennedy, S | 1 |
Eisen, AZ | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study[NCT04129931] | Phase 2 | 600 participants (Anticipated) | Interventional | 2019-12-19 | Recruiting | ||
Prescribing Asthma Controller Medication According to Gene Status to Improve Quality of Life in Young People With Asthma[NCT02758873] | 241 participants (Actual) | Interventional | 2016-02-29 | Completed | |||
Childhood Asthma Research and Education (CARE) Network Trial - Best Add-On Therapy Giving Effective Response (BADGER)[NCT00395304] | Phase 3 | 182 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Asthma quality of life is measured as the average of 23 questions, each of which is scored from 1 (worse) to 7 (best) (NCT00395304)
Timeframe: Measured during the last 12 weeks of each 16-week treatment period
Intervention | units on a scale (Mean) |
---|---|
2xICS | 0.2 |
1xICS + LABA | 0.3 |
1xICS + LTRA | 0.3 |
The ACT consists of five items, each scored as 1 (worst) to 5 (best). The five items are averaged. (NCT00395304)
Timeframe: Measured during the last 12 weeks of each 16-week treatment period
Intervention | units on a scale (Mean) |
---|---|
2xICS | 1.49 |
1xICS + LABA | 1.87 |
1xICS + LTRA | 1.69 |
(NCT00395304)
Timeframe: Measured during the last 12 weeks of each 16-week treatment period
Intervention | percentage points (Mean) |
---|---|
2xICS | 2.84 |
1xICS + LABA | 4.87 |
1xICS + LTRA | 2.29 |
Change from baseline in the impulse oscillometry resistance at 5 Hertz, measured in kiloPascals per liters per second (NCT00395304)
Timeframe: Measured during the last 12 weeks of each 16-week treatment period
Intervention | kiloPascals per liters per second (Mean) |
---|---|
2xICS | -0.08 |
1xICS + LABA | -0.09 |
1xICS + LTRA | -0.06 |
The methacholine PC20 is the concentration of methacholine that causes a 20% decrease in the pre-bronchodilator FEV1. The logarithm base 2 transformation converts the PC20 into doubling dilutions. (NCT00395304)
Timeframe: Measured during the last 12 weeks of each 16-week treatment period
Intervention | doubling dilutions (Mean) |
---|---|
2xICS | 1.11 |
1xICS + LABA | 1.20 |
1xICS + LTRA | 1.00 |
(NCT00395304)
Timeframe: Measured during the last 12 weeks of each 16-week treatment period
Intervention | percentage points (Mean) |
---|---|
2xICS | 4.44 |
1xICS + LABA | 6.26 |
1xICS + LTRA | 4.04 |
(NCT00395304)
Timeframe: Measured during the last 12 weeks of each 16-week treatment period
Intervention | natural logarithm of parts per billion (Mean) |
---|---|
2xICS | -0.04 |
1xICS + LABA | -0.05 |
1xICS + LTRA | -0.02 |
PEFR variability is calculated as 100% times the difference between the evening and morning PEFR values, divided by the average of the evening and morning PEFR values, i.e., PEFR variability = 100% x (morning PEFR - evening PEFR)/((morning PEFR + evening PEFR)/2) (NCT00395304)
Timeframe: Measured during the last 12 weeks of each 16-week treatment period
Intervention | percentage points (Mean) |
---|---|
2xICS | 2.09 |
1xICS + LABA | 1.61 |
1xICS + LTRA | 1.72 |
(NCT00395304)
Timeframe: Measured during the last 12 weeks of each 16-week treatment period
Intervention | percentage points (Mean) |
---|---|
2xICS | -0.2 |
1xICS + LABA | -1.2 |
1xICS + LTRA | -0.8 |
(NCT00395304)
Timeframe: Measured during the last 12 weeks of each 16-week treatment period
Intervention | ratio (Mean) |
---|---|
2xICS | 0.98 |
1xICS + LABA | 2.13 |
1xICS + LTRA | 0.55 |
(NCT00395304)
Timeframe: Measured during the last 12 weeks of each 16-week treatment period
Intervention | percentage points (Mean) |
---|---|
2xICS | 0.26 |
1xICS + LABA | 1.07 |
1xICS + LTRA | -0.84 |
(NCT00395304)
Timeframe: Measured during the last 12 weeks of each 16-week treatment period
Intervention | percentage points (Mean) |
---|---|
2xICS | -1.00 |
1xICS + LABA | -1.58 |
1xICS + LTRA | -1.56 |
An asthma exacerbation was defined as the administration of a course of oral/systemic prednisone for the treatment of asthma. (NCT00395304)
Timeframe: Measured during the last 12 weeks of each 16-week treatment period
Intervention | Participants (Count of Participants) |
---|---|
2xICS | 49 |
1xICS + LABA | 35 |
1xICS + LTRA | 37 |
One treatment period was ranked as better than another if the total amount of prednisone received during the period was at least 180 mg less, if the number of annualized asthma-control days during the final 12 weeks of the period was increased by at least 31 days, or if the FEV1 at the end of the period was at least 5% higher. If the prednisone threshold was met, then we ignored the number of asthmacontrol days and the FEV1. If the threshold for asthma-control days was met, then we ignored the FEV1. Otherwise, the order of response was determined by the FEV1. (NCT00395304)
Timeframe: Measured during the last 12 weeks of each 16-week treatment period
Intervention | Participants (Number) |
---|---|
All Participants | 161 |
2 trials available for albuterol and Dermatitis, Eczematous
Article | Year |
---|---|
Eczema and race as combined determinants for differential response to step-up asthma therapy.
Topics: Acetates; Adolescent; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Black or African Ame | 2014 |
Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids.
Topics: Acetates; Administration, Inhalation; Administration, Oral; Adolescent; Adrenergic beta-Agonists; Al | 2010 |
Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids.
Topics: Acetates; Administration, Inhalation; Administration, Oral; Adolescent; Adrenergic beta-Agonists; Al | 2010 |
Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids.
Topics: Acetates; Administration, Inhalation; Administration, Oral; Adolescent; Adrenergic beta-Agonists; Al | 2010 |
Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids.
Topics: Acetates; Administration, Inhalation; Administration, Oral; Adolescent; Adrenergic beta-Agonists; Al | 2010 |
Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids.
Topics: Acetates; Administration, Inhalation; Administration, Oral; Adolescent; Adrenergic beta-Agonists; Al | 2010 |
Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids.
Topics: Acetates; Administration, Inhalation; Administration, Oral; Adolescent; Adrenergic beta-Agonists; Al | 2010 |
Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids.
Topics: Acetates; Administration, Inhalation; Administration, Oral; Adolescent; Adrenergic beta-Agonists; Al | 2010 |
Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids.
Topics: Acetates; Administration, Inhalation; Administration, Oral; Adolescent; Adrenergic beta-Agonists; Al | 2010 |
Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids.
Topics: Acetates; Administration, Inhalation; Administration, Oral; Adolescent; Adrenergic beta-Agonists; Al | 2010 |
1 other study available for albuterol and Dermatitis, Eczematous
Article | Year |
---|---|
Leukocyte and lymphocyte cyclic AMP responses in atopic eczema.
Topics: Adolescent; Adult; Albuterol; Cyclic AMP; Eczema; Epinephrine; Humans; In Vitro Techniques; Isoprote | 1977 |